Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis
Annals of Nuclear Medicine · 2026
DOI: 10.1007/s12149-025-02100-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2026. Verfasst von Sepideh Shafiei und 1 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. sshafiei@aeoi.org.ir. Hauptthemen laut MEDLINE: Alpha Particles, Thorium, Neoplasms, Radiation Dosage. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Producing several alpha-emitting isotopes in the decay chain of 227Th-based radiopharmaceuticals has increased the complexity of determining the optimal therapeutic dose. This research aims to assess the contribution of each thorium progeny to the cumulative dose in the tumor over time. This assessment will help determine the required injected activity and the appropriate characteristics of a 227Th-based radiopharmaceutical that can provide an adequate dose to induce sufficient cytotoxicity for effective treatment. METHODS: The cumulative dose in tumors of various sizes (with radii of 0.6, 1.2, and 1.8 cm) resulting from the decay of 227Th was calculated using MCNPX. The radial and temporal distribution of the absorbed dose within the tumor was studied, along with the contribution of each radioisotope to the cumulative dose over time throughout the tumor. Validation of the calculation was performed by determining the cumulative dose of 227Th-rituximab based on the experimental biodistribution, tumor size and mice weight reported in the literature. RESULTS: The cumulative dose within the tumor increases over time and is inversely proportional to the tumor's volume. The radial distribution of the cumulative dose within the tumor indicated that 227Th-based radiopharmaceuticals do not harm the healthy tissue surrounding the tumor. CONCLUSIONS: By taking into account the size of the tumor and the required therapeutic dose, the proposed calculation method can be employed to determine the necessary injected activity and characteristics of a radiopharmaceutical. This includes identifying a suitable retention time and tumor uptake to improve therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. sshafiei@aeoi.org.ir.
- Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran.
Zitieren
APA
Shafiei, S., & Yousefnia, H. (2026). Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02100-0
Vancouver
Shafiei S, Yousefnia H. Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis. Annals of Nuclear Medicine. 2026. doi:10.1007/s12149-025-02100-0
BibTeX
@article{Shafiei2026,
author = {Shafiei, Sepideh and Yousefnia, Hassan},
title = {Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis},
journal = {Annals of Nuclear Medicine},
year = {2026},
doi = {10.1007/s12149-025-02100-0}
}
EUVIMED